IPSEN (OTCMKTS:IPSEY) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?

Key Points

• IPSEN's share price has recently surpassed its 200-day moving average of $29.72, reaching a high of $34.09 during trading.
• The company announced an increase in its dividend, with investors receiving a payment of $0.2896 per share, a significant rise from the previous dividend of $0.23.
• IPSEN operates as a biopharmaceutical company focusing on oncology, neuroscience, and rare diseases, with multiple products in varying stages of clinical trials.

Shares of IPSEN (OTCMKTS:IPSEY - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $29.72 and traded as high as $34.09. IPSEN shares last traded at $34.09, with a volume of 2,170 shares traded.

IPSEN Stock Performance

The business's 50 day moving average price is $31.28 and its 200 day moving average price is $29.78.

IPSEN Increases Dividend

The business also recently announced a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were paid a dividend of $0.2896 per share. This is an increase from IPSEN's previous dividend of $0.23. This represents a dividend yield of 97.0%. The ex-dividend date of this dividend was Monday, June 9th.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.